Cargando…
Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation
INTRODUCTION: Fosaprepitant, an intravenous (IV) aprepitant prodrug for chemotherapy-induced nausea and vomiting prophylaxis, is associated with systemic and infusion-site reactions attributed in part to its surfactant, polysorbate 80. HTX-019 is an IV aprepitant formulation free of polysorbate 80 a...
Autores principales: | Ottoboni, Tom, Keller, Mary Rose, Cravets, Matt, Clendeninn, Neil, Quart, Barry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837372/ https://www.ncbi.nlm.nih.gov/pubmed/29535504 http://dx.doi.org/10.2147/DDDT.S155875 |
Ejemplares similares
-
Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
por: Langford, Patrick, et al.
Publicado: (2010) -
Safety Profile of HTX-019 Administered as an Intravenous Infusion in Patients With Cancer: A Retrospective Analysis
por: Calcanes, George, et al.
Publicado: (2019) -
Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review
por: Walton, Gary D.
Publicado: (2019) -
Response to the letter to the editor by Hafer and Johnson concerning ‘Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain’
por: Ottoboni, Thomas, et al.
Publicado: (2020) -
Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis
por: Burns, Derek, et al.
Publicado: (2020)